Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692656 | 0.88 | NQO1 (0.54) | TDP1NQO1ALDH1A1CYP3A4KDM4E | |
| SCHEMBL15251098 | 0.85 | GAA (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12311778 | 0.84 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13256249 | 0.84 | NQO1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13924822 | 0.82 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12301282 | 0.82 | CYSLTR2 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8888440 | 0.82 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12093645 | 0.82 | CA12 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29837419 | 0.81 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL140807 | 0.81 | CA12 (0.65) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346708-A1 | STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES | ONCOLYZE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346708-A1 | STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES | ONCOLYZE, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021141789-A1 | STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES | ONCOLYZE, INC. (US) | 2021-07-15 | — | — | WO | disclosed |
| US-20210128754-A1 | COMPOSITIONS FOR USE IN LYSIS OF SELECTIVE CANCER CELLS | ONCOLYZE, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2019195851-A1 | COMPOSITIONS FOR USE IN LYSIS OF SELECTIVE CANCER CELLS | ONCOLYZE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20180037843-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822327-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160186093-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2016-06-30 | — | — | US | disclosed |
| US-9309487-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140378360-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2014-12-25 | — | — | US | disclosed |
| US-8912350-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2423917-B1 | Use of chemically bonded dyes in holographic data storage media | GEN ELECTRIC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120329696-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE COMPANY, THE | 2012-12-27 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037843-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CA12 2663/4885CA1 4322/4885CA2 3706/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | CA12 4788/4885CA1 4574/4885CA2 4183/4885 |
| US-20210128754-A1 | COMPOSITIONS FOR USE IN LYSIS OF SELECTIVE CANCER CELLS | CASP3, GZMB, CASP9 | CA12 1894/4885CA1 3430/4885CA2 4047/4885 |
| US-20120329696-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | CA12 2663/4885CA1 4322/4885CA2 3706/4885 |
| US-20230346708-A1 | STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES | TAP2, MASP2, MAN2A1 | CA12 834/4885CA1 2013/4885CA2 1512/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | CA12 4836/4885CA1 4827/4885CA2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.